Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Incidence of the common cold Number of participants with common cold by group · young, healthy men in a military facility
It is very uncertain whether virus vaccines changes incidence of the common cold Number of participants with common cold… compared with placebo (very low certainty).
1 finding from 1 review
Vaccine safety · young, healthy men in a military facility
1 finding from 1 review
Mortality: vaccine related and all cause ‐ not reported · young, healthy men in a military facility
The review found no eligible studies for this question.
1 finding from 1 review
Pain alterationa · people with sickle cell disease
1 finding from 1 review
Life‐threatening illness · people with sickle cell disease
1 finding from 1 review
Measures of HbF · people with sickle cell disease
1 finding from 1 review
Measures of ANC · people with sickle cell disease
1 finding from 1 review
Health status and quality of life · people with sickle cell disease
1 finding from 1 review
Adverse events or toxicity: differences in rates of specific adverse events · people with sickle cell disease
1 finding from 1 review
Combined outcome of mortality or BPD at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Mortality at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Open‐label use of systemic corticosteroids · preterm infants
It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18‐85)
It is very uncertain whether comparison 5: SNRIs changes treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (very low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 6: SSRIs probably leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (moderate certainty).
1 finding from 1 review